General Health

General health issues, Medical conditions, Research and studies and more

Mental Health

Natural Medicine

Nutritional supplements, Herbs, Alternative medicine and more…

Wellness & Lifestyle

Nutrition, Diets, Healthy living, Detox, Exercise and Physical Fitness, Sports Fitness and more…

Women’s Health

Relationships, Pregnancy, Birth control, Menopause and more

Home » Information, News

Rare Immune Cell Involved in Multiple Sclerosis

Article / Review by on August 13, 2012 – 6:10 pmNo Comments

Rare Immune Cell Involved in Multiple Sclerosis

A unique type of immune cell may contribute to multiple sclerosis (MS), researchers report. The discovery helps explain the effects of one of the newest experimental therapies for MS and could lead to improved treatments for MS and related disorders.

Rare Immune Cell Involved in Multiple Sclerosis

MS is an autoimmune disease in which the body’s own immune system attacks the brain and spinal cord, resulting in nerve damage. Nearly 400,000 people in the U.S. are affected by the disease. Symptoms include problems with coordination and balance, muscle weakness, numbness or tingling, vision loss and slurred speech. In the worst cases, MS can cause partial or complete paralysis.

In 2007, NIH-funded researchers implicated the interleukin 2 (IL-2) receptor in MS. One function of IL-2 is to mobilize immune system T cells to expand and attack. The drug daclizumab blocks the IL-2 receptor. Ongoing clinical trials have shown that it helps quiet the autoimmune response in MS patients.

When daclizumab was first tested against MS, researchers theorized that it was acting directly on T cells, shutting off their IL-2 receptors. However, the IL-2 receptor is found on several types of immune cells. The drug’s precise effects on the legions of cells that make up the immune system aren’t well understood.

Recent work from a team led by Dr. Bibiana Bielekova of NIH’s National Institute of Neurological Disorders and Stroke (NINDS) revealed that daclizumab’s effects on T cells are mostly indirect. They found that the drug also affects cells of the innate immune system—the rapid, blunt first line of defense against infection. One such effect is to stimulate cells called natural killer cells.

In their new study, Bielekova’s team investigated levels of innate immune cells in people taking daclizumab. The researchers obtained blood samples from daclizumab-treated MS patients, untreated MS patients and healthy subjects. They then isolated innate immune cells for classification. Their results appeared on August 1, 2012, in Science Translational Medicine.

The scientists found that MS patients had higher levels of an innate immune cell called lymphoid tissue inducer (LTi) than did healthy subjects. LTi cells direct lymph node development during early life, but their role during adulthood isn’t clear. In MS patients receiving daclizumab, the number of LTi cells was lower than in those who weren’t taking the drug. Daclizumab appears to steer the body away from producing LTi cells in favor of producing natural killer cells.

Patients receiving daclizumab also had reduced signs of inflammation in the cerebrospinal fluid that surrounds the brain. The finding provides an indirect link between LTi cells and brain inflammation in MS.

This study is the first to link LTi cells to an autoimmune disease. “While further study is required to confirm the role of LTi cells in autoimmunity, our results point to the cells as a promising target for the development of new drugs to treat autoimmune disorders,” says Bielekova.

###

*  The above story is reprinted from materials provided by National Institutes of Health (NIH)
** The National Institutes of Health (NIH) , a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency—making important discoveries that improve health and save lives. The National Institutes of Health is made up of 27 different components called Institutes and Centers. Each has its own specific research agenda. All but three of these components receive their funding directly from Congress, and administrate their own budgets.

More about National Institutes of Health (NIH)

Tags: , , ,

Leave a comment!

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>